PharmAthene pharmathene.com

PharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.

PharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax mon...Show all

See All Exits Recent Exits

Phone: 410-269-2600

Fax:

One Park Place
Suite 450
Annapolis, 21401
Maryland, United States

PharmAthene - Investments & Acquisitions

Show Real Data PharmAthene Investments
See all Recent Investments
Date Company Round Amount Co-investors
2017-05-04AltimmuneReverse Merger
See all 1 investments